Corcept Q3 revenue $123.6M (+22% YoY); raises FY 2023 guidance to $470-$480M

CORCEPT THERAPEUTICS INC

2023-Q3 EPS reported $0.66 revenue$346,970,000

Revenue $123.6M (+22% YoY); net income $31.4M ($0.28 diluted EPS) vs $34.6M ($0.30) in Q3 2022.
FY 2023 revenue guidance raised to $470-$480M from previous $455-$470M.
Cash and investments $414.8M at Sept 30, up from $363.3M end of prior quarter.
GRACE Phase 3 enrollment complete; NDA for relacorilant in Cushing's expected Q2 2024.
Key 2024 trial readouts: GRADIENT (mid-2024), ROSELLA, DAZALS (year-end 2024), CATALYST prevalence (Q1 2024).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

CORCEPT THERAPEUTICS INC reported the quarter ended September 30, 2023 results: revenue $123.6 million, net income $31.4 million, EPS $0.28 (diluted). Guidance raised.

Period: the quarter ended September 30, 2023
Revenue: $123.6 million
Net income: $31.4 million
EPS: $0.28 (diluted)
Guidance: raised
Result: reported results

Exact text from the filing

and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended September 30, 2023. Financial Results • Revenue of $123.6 million, a 22 percent increase from third quarter 2022 • Increase in 2023 revenue guidance to $470 – $480 million, from $455 – $470 million • Net income per common share of $0.28

View on SEC.gov

Browse all earnings releases →

CORCEPT THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001628280-23-035979

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.